The number of patients with end-stage renal disease is increasing at the rate of 7 to 8 percent per year in the United States.1 Renal transplantation is the treatment of choice for most of these patients, but the number of kidneys available for transplantation is limited.2 Since 1988, there has been a growing discrepancy between the number of transplantations performed and the number of patients awaiting transplantation, underscoring the need to maximize graft survival.2 The short-term outcome of renal transplantation has improved substantially in the past 15 years. The introduction of cyclosporine for the prevention of acute and chronic rejection . . .
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below